Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid
NCT ID: NCT00984191
Last Updated: 2011-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
15 participants
INTERVENTIONAL
2010-03-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
NCT01149161
CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer
NCT03359668
ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
NCT01730638
I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer
NCT06443866
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
NCT06961084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
99mTc positive
99mTechnetium-MIBI SPECT-CT positive compare : Scan - Pathologic report
99mTc-MIBI SPECT-CT
99mTc-MIBI SPECT-CT for abnormal cervical lymph node
99mTc Negative_Neck dissection
99mTc Negative but have neck dissection indication compare : 99mTc - Pathologic report
99mTc-MIBI SPECT-CT
99mTc-MIBI SPECT-CT for abnormal cervical lymph node
99mTc Negative_No neck dissection
99mTc Negative and No other indication for neck dissection compare : 99mTc - 7. 131I (post-treatment) whole body scan
99mTc-MIBI SPECT-CT
99mTc-MIBI SPECT-CT for abnormal cervical lymph node
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
99mTc-MIBI SPECT-CT
99mTc-MIBI SPECT-CT for abnormal cervical lymph node
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Bleeding abnormality
* Prior history of head and neck cancer
* can not perform 99mTechnetium-MIBI SPECT-CT
* can not perform 131I remnant Ablation
* Prior any head and neck surgery within 3 months
* Prior deep neck infection within 3 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Otolaryngology , Faculty of Medicine , Chulalongkorn University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Napadon Tangjaturonrasme, Otolaryngologist
Role: PRINCIPAL_INVESTIGATOR
Department of Otolaryngology , Faculty of Medicine , Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King Chulalongkorn Hospital
Pathumwan, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NapadonChula_01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.